DataRobot vs a2z Radiology AI
Side-by-side comparison of AI visibility scores, market position, and capabilities
$285M revenue 2024; $225M ARR (+12.5% YoY slowdown); $6.3B valuation; $1.3B total funding; 850 customers; 969 employees; AutoML market $1B 2023 to $6.4B 2028 (+45% CAGR); enterprise AI platform
About
DataRobot is an enterprise AI and machine learning platform company founded in 2012 in Boston by Jeremy Achin and Tom de Godoy. The company pioneered the AutoML category, with a mission to democratize AI by automating the model development lifecycle so that data scientists, analysts, and business users at any organization could build, deploy, and monitor predictive models without requiring deep ML expertise for every step.\n\nDataRobot's platform covers the full AI lifecycle: automated feature engineering and model training across dozens of algorithms, model explainability and bias detection, one-click deployment to production, and continuous monitoring for model drift and data quality degradation. The company has expanded beyond AutoML into a broader AI platform that supports generative AI use cases, LLM evaluation, and AI governance workflows. DataRobot serves more than 850 enterprise customers across financial services, healthcare, manufacturing, and the public sector, with use cases spanning credit risk modeling, demand forecasting, predictive maintenance, and clinical decision support.\n\nDataRobot reported $285 million in revenue for 2024, with $225 million in ARR, and carries a $6.3 billion valuation on $1.3 billion in total funding. The company has navigated multiple leadership transitions and repositioning efforts, ultimately establishing itself as a durable enterprise AI platform. Its depth of AutoML capabilities, enterprise governance features, and broad deployment integrations keep it competitive against both specialist ML platforms and the AI tools embedded in major cloud providers.
a2z Radiology AI raised $20M in 2025 for its whole-body AI that simultaneously screens for 24+ conditions across CT scans — from incidental cancers to cardiovascular risk — in a single automated read.
About
a2z Radiology AI has developed a whole-body CT analysis platform that simultaneously screens for over 24 medical conditions across a single CT scan, including incidental cancers, coronary artery disease, aortic aneurysm, bone density loss, and organ abnormalities. The AI acts as a second reader that radiologists can use to catch incidental findings that fall outside the primary reason for a scan — a major source of missed diagnoses.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.